MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 24, 2007; DOI: 10.1124/mol.107.039594


0026-895X/08/7301-243-251$20.00
Mol Pharmacol 73:243-251, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.039594v1
73/1/243    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Lin, Z. P.
Right arrow Articles by Sartorelli, A. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, Z. P.
Right arrow Articles by Sartorelli, A. C.

Disruption of cAMP and Prostaglandin E2 Transport by Multidrug Resistance Protein 4 Deficiency Alters cAMP-Mediated Signaling and Nociceptive Response

Z. Ping Lin, Yong-Lian Zhu, Dennis R. Johnson, Kevin P. Rice, Timothy Nottoli, Bryan C. Hains, James McGrath, Stephen G. Waxman, and Alan C. Sartorelli

Department of Pharmacology and Developmental Therapeutics Program (Z.P.L., Y.-L.Z., D.R.J., A.C.S.), Section of Comparative Medicine (T.N., J.M.), Cancer Center, and Department of Neurology (B.C.H., S.G.W), Yale University School of Medicine, New Haven, Connecticut, and Department of Chemistry, Colby College, Waterville, Maine (K.P.R.)

Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the MRP/ATP-binding cassette family serving as a transmembrane transporter involved in energy-dependent efflux of anticancer/antiviral nucleotide agents and of physiological substrates, including cyclic nucleotides and prostaglandins (PGs). Phenotypic consequences of mrp4 deficiency were investigated using mrp4-knockout mice and derived immortalized mouse embryonic fibroblast (MEF) cells. Mrp4 deficiency caused decreased extracellular and increased intracellular levels of cAMP in MEF cells under normal and forskolin-stimulated conditions. Mrp4 deficiency and RNA interference-mediated mrp4 knockdown led to a pronounced reduction in extracellular PGE2 but with no accumulation of intracellular PGE2 in MEF cells. This result was consistent with attenuated cAMP-dependent protein kinase activity and reduced cyclooxygenase-2 (Cox-2) expression in mrp4-deficient MEF cells, suggesting that PG synthesis is restrained along with a lack of PG transport caused by mrp4 deficiency. Mice lacking mrp4 exhibited no outward phenotypes but had a decrease in plasma PGE metabolites and an increase in inflammatory pain threshold compared with wild-type mice. Collectively, these findings imply that mrp4 mediates the efflux of PGE2 and concomitantly modulates cAMP mediated signaling for balanced PG synthesis in MEF cells. Abrogation of mrp4 affects the regulation of peripheral PG levels and consequently alters inflammatory nociceptive responses in vivo.


Received July 3, 2007; accepted October 22, 2007

Address correspondence to: Alan C. Sartorelli, Department of Pharmacology, Yale University School of Medicine, 333 Cedar St., New Haven, CT 06520. E-mail: alan.sartorelli{at}yale.edu.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics